The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Rosinskaia A.V.

Kafedra nevrologii Rossiĭskoĭ meditsinskoĭ akademii poslediplomnogo obrazovaniia;
Tsentr kstrapiramidnykh zabolevaniĭ, Moskva

Vasenina E.E.

Rossiĭskaia meditsinskaia akademiia poslediplomnogo obrazovaniia, Moskva

Khaybullin T.N.

Semey State Medical University, Semey, Kazahstan

Levin O.S.

Rossiĭskaia meditsinskaia akademiia poslediplomnogo obrazovaniia

Rate of progression of Parkinson’s disease with early and delayed prescription of levodopa preparations

Authors:

Rosinskaia A.V., Vasenina E.E., Khaybullin T.N., Levin O.S.

More about the authors

Read: 1584 times


To cite this article:

Rosinskaia AV, Vasenina EE, Khaybullin TN, Levin OS. Rate of progression of Parkinson’s disease with early and delayed prescription of levodopa preparations. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(6‑2):77‑81. (In Russ.)
https://doi.org/10.17116/jnevro201811806277

Recommended articles:
Sleep diso­rders in patients with Lewy body deme­ntia and Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):81-87
Pathomorphosis of the Parkinson’s disease against the background of DBS STN. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):21-27
Neuroinflammatory and neurodegenerative aspe­cts of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):102-111
Schi­zophrenic spectrum diso­rders and Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):136-141
Art and creativity in Parkinson’s disease: the mysterious effe­cts of dopa­mine. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):13-20
Correlation of motor symptoms and cardiovascular dysfunction in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):59-67
Effect of uric acid on the progression of Parkinson’s disease: Myth or reality?. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):7-14

References:

  1. Levin OS, Fedorova NV. Parkinsons disease. M.: Medpress-inform; 2016. (In Russ.)
  2. Fox SH, Katzenschlager R, Lim S, Barton B, de Bie RM, Seppi K, Coelho M, Sampaio C. International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson’s disease. Movement Disorders. 2018 Mar 23. Epub ahead of print. https://doi.org/10.1002/mds.27372
  3. Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A. Impulse control disorder in patients with Parkinson’s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85:840-844. https://doi.org/10.1136/jnnp-2013-306787
  4. Worth P. Results of the early stage PD MED study: revelation or recapitulation? Practical Neurology. 2015;15:408-410. https://doi.org/10.1136/practneurol-2015-001149
  5. Tambasco N, Romoli M, Calabresi P. Levodopa in Parkinson’s Disease: Current Status and Future Developments. Current Neuropharmacology. Epub ahead of print. https://doi.org/10.2174/1570159X15666170510143821
  6. Hoehn M, Yahr M. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427-442. https://doi.org/10.1212/wnl.17.5.427
  7. Zhao YJ, Wee HL, Chan YH, Seah SH, Au WL, Lau PN, Pica EC, Li SC, Luo N, Tan LC. Progression of Parkinson’s disease as evaluated by Hoehn and Yahr stage transition times. Movement Disorders. 2010;25(6):710-716. https://doi.org/10.1002/mds.22875
  8. Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, Van Hilten JJ, LaPelle N. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Movement Disorders. 2007;22(1):41-47. https://doi.org/10.1002/mds.21198
  9. McRae C, Diem G, Vo A, O’Brien C, Seeberger L. Schwab & England: Standardization of administration. Movement Disorders. 2000;15:335-336.
  10. Cognitive assessment, the Folstein Mini-Mental State Examination (MMSE). Clinical Skills for OSCEs: Second Edition; 2006. https://doi.org/10.1201/b17661-53
  11. Manos P. The ten-point clock test: a quick screen for cognitive impairment in medical and surgical patients. The American Journal of Geriatric Psychiatry. 1994;7:49. https://doi.org/10.1097/00019442-199911001-00142
  12. Glozman JM. Quantitative and qualitative integration of Lurian procedures. Neuropsychol Rev. 1999;9:23. https://doi.org/10.1023/A:1025638903874
  13. Beck C, Gable R. Postpartum Depression Screening Scale: Development and Psychometric Testing. Nursing Research. 2000;49(5):272-282. https://doi.org/10.1097/00006199-200009000-00006
  14. Starkstein S. Apathy in Parkinson’s disease: Diagnostic and etiological dilemmas. Movement Disorders. 2012;27(2):174-178. https://doi.org/10.1002/mds.24061
  15. Espay AJ, Lang AE. Common Myths in the Use of Levodopa in Parkinson Disease: When Clinical Trials Misinform Clinical Practice. JAMA Neurol. 2017;74(6):633-634. https://doi.org/10.1001/jamaneurol.2017.0348
  16. Parkinson Study Group. A Randomized Controlled Trial Comparing Pramipexole with Levodopa in Early Parkinson’s Disease: Design and Methods of the CALM-PD Study. Clinical Neuropharmacology. 2000;23(1):34-44. https://doi.org/10.1097/00002826-200001000-00007
  17. Whone A, Watts R, Stoessl A, Davis M, Reske S, Nahmias C, Lang A, Rascol O, Ribeiro M, Remy P, Poewe W, Hauser R, Brooks D. Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Annals of Neurology. 2003;54(1):93-101. https://doi.org/10.1002/ana.10609
  18. Zhang J, Tan LC-S. Revisiting the Medical Management of Parkinson’s Disease: Levodopa versus Dopamine Agonist. Current Neuropharmacology. 2016;14(4):356-363. https://doi.org/10.2174/1570159X14666151208114634
  19. Mostile G, Nicoletti A, Dibilio V, Luca A, Raciti L, Sciacca G, Cicero C, Vasta R, Donzuso G, Contrafatto D, Zappia M. Switching L-dopa Therapy from Pulsatile to Pulse Administration Reduces Motor Complications in Parkinsonʼs Disease. European Journal of Neurology. 2014;21(1)104-387. https://doi.org/10.1097/wnf.0000000000000186
  20. Antonini A, Fung V, Boyd J, Slevin J, Hall C, Chatamra K, Eaton S, Benesh J. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson’s disease patients. Movement Disorders. 2016;31(4):530-537. https://doi.org/10.1002/mds.26528
  21. Aquino CC, Fox SH. Clinical spectrum of levodopa-induced complications. Movement Disorders. 2015;30:80-89. https://doi.org/10.1002/mds.26125
  22. Yao Z, Shao Y, Han X. Freezing of gait is associated with cognitive impairment in patients with Parkinson disease. Neuroscience Letters. 2017;656:126-130. https://doi.org/10.1016/j.neulet.2017.07.004
  23. Peterson DS, King LA, Cohen RG, Horak FB; Cognitive Contributions to Freezing of Gait in Parkinson Disease: Implications for Physical Rehabilitation. Physical Therapy. 2016;96(5):659-670. https://doi.org/10.2522/ptj.20140603

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.